Skip Ribbon Commands
Skip to main content
 
 

 

 
  • Prof. Efrat Dagan

    Prof. Efrat Dagan

    The Cheryl Spencer Department of Nursing
    972-4-8288003
    EDAGAN@UNIV.HAIFA.AC.IL
    CV File
    http://lecturers.haifa.ac.il/CV/Efrat_Dagan-biographical_sketch_2014.doc, https://lecturers.haifa.ac.il/CV/Efrat_Dagan-biographical_sketch_2014.doc

Head of Department of Nursing

Senior Lecture

Research Areas

  • Hereditary breast-ovarian cancer;
  • Cancer genetics;
  • Human genetics;
  • Genetic susceptibility to late onset diseases;
  • Genetic counseling.

Education

Date
Degree
Name of Institution Department
Period of Study
1988
B.N., R.N.
Hebrew University of Jerusalem
School of Nursing
1984 - 1988
1993
M.Sc.
Technion - Israel Institute of Technology, Haifa
Faculty of Medical Sciences
Pharmacology
1989 - 1993
2000
Ph.D.
Technion - Israel Institute of Technology, Haifa
Faculty of Medical Sciences
Human Genetics

1995 - 2000

 

Grants and Awards

2010 - V.P.R. Grant, Technion - Genetic Susceptibility Markers in Parkinson Disease, (Co PI with Prof. Ruth Gershoni-Baruch and Prof. Judith Peretz-Aharon, 8000$.

 

Publications

Books

Dagan E and Gershoni-Baruch R (2010). Genetic disorders among Jews from Arab countries. In AS Teebi (Ed.), Genetic disorders among Arab population (2nd ed.)  (pp. 677-705). New-York, NY: Springer-Verlag.

Articles

Weizman R, Laor N, Karp L, Dagan E, Reiss A, Dar ED, Wolmer L, Gavish M (1994). Alteration of platelet benzodiazepine receptor by stress of war. American Journal of Psychiatry. 151:5.

Weizman R, Dagan E, Snyder HS, Gavish M (1997). Impact of pregnancy and lactation on GABA-A receptor and central-type and peripheral-type benzodiazepine receptors. Brain Research. 752:307-14.

Dagan E, Gershoni-Baruch R (1997). BRCA1 and BRCA2 susceptibility genes for breast and ovarian cancer. Harefuah. 133:455-7 (in Hebrew).

Gershoni-Baruch R, Dagan E, Kepten I, Freid J (1997). Co-segregation of BRCA1 185delAG mutation and BRCA2 6174delT in one single family. European Journal of Cancer. 33:2283-4.

Friedman E, Bruchim Bar-Sade R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, Peretz T, Lerer I, Wienberger N, Shushan A, Abelliovich AD - The Israeli Breast Cancer Consortium (1998). Double and compound heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. American Journal of Human Genetics. 63:1224-7.

Weizman R, Dagan E, Kaplan B, Karp L, Malmud S, Snyder SH, Gavish M (1999). Platelet peripheral-type benzodiazepine receptors in pregnancy and lactation. Neuropsychopharmacology. 21: 513-8.

Gershoni-Baruch R, Dagan E, Freid J, Kepten I, Robinson E (1999). BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. European Journal of Human Genetics. 7:833-6.

Gershoni-Baruch R, Dagan E, Bruchim Bar-Sade R, Fried G, Sverdlov-Shiri R, Zelickson G, Friedman E (‏2000). Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared to familial early breast cancer. European Journal of Cancer. 36:983-6.

Gershoni-Baruch R, Patael Y, Dagan E, Figer A, Kasinetz L, Kaduri E, Bruchim Bar-Sade R, Friedman E (2000). Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. British Journal of Cancer. 83:153-5.

Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kaduri E, Friedman E (2000). Association of the C677T polymorphism in the MTHFR gene and/or ovarian cancer risk in Jewish women. European Journal of Cancer. 36:2313-6.

Shiri Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E (2000). Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Human Mutation. 16:491-501.

Sverdlov-Shiri R, Bruchim Bar-Sade R, Gershoni-Baruch R, Barshack I, Hirsh-Yehezkel G, Dagan E, Feimesser M, Figer A, Friedman E (2000). Genetic analyses of male breast cancer in Israel. Genetic Testing. 4:313-7.

Levi-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Renbaum P, Gershoni-Baruch R (2001). A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proceeding National Academy of Science. 98:3232-6.

Dagan E and Gershoni-Baruch R (2001). Hereditary breast/ovarian cancer – pitfalls in genetic counseling. Clinical Genetics. 60:310-3.

Dagan E and Gershoni-Baruch R (2002b). Anticipation in hereditary breast cancer. Clinical Genetics. 62:147-50.

Drach-Zehavi A, Dagan E (2002). From caring to managing and beyond: An examination of the head nurse's role. Journal of Advanced Nursing. 38:19-28.

Dagan E, Friedman E, Carmi N, Gershoni-Baruch R (2002). Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: Association with breast/ovarian cancer phenotype. European Journal of Human Genetics. 10:724-8.

Gal I, Gershoni-Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E (2004). The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Familial Cancer. 3:11-4.

Dagan E and Gil S (2004). Being a BRCA1/2 mutation carrier: Women's psychological distress and ways of coping. Journal of Psychosocial Oncology 22:93-106.

Quintana-Murci L , Gal I, Bakhan T, Quach H, Sayar SH, Shiri-Sverdlov R, Baruch RG, McElreavey K, Dagan E, Narod S, Friedman E (2005). The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews. Familial Cancer. 4:85-8.

Karban A, Dagan E, Eliakim R, Herman A, Nesher S, Berkovitz D, Shamir R, Gershoni-Baruch R (2005). Prevalence and significance in the familial Mediterranean fever gene in patients with Crohn's disease. Genes and Immunity. 6:134-39.

Simchoni S , Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E (2006). Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proceeding National Academy of Science U S A. 7;103:3770-4.

Gal I, Kimmel G, Gershoni-Baruch R, Papa MZ, Dagan E, Shamir R, Friedman E. (2006). A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women. European Journal of Cancer. 42:1129-34.

Dagan E, Brik R, Broza Y, Gershoni-Baruch R (2006). Henoch-Schonlein purpura: polymorphisms in thrombophilia genes. Pediatric Nephrology 21:1117-21.

Dagan E, Laitman Y,Levanon N,Feuer A,Sidi AA,Baniel J, Korach Y, Ben Baruch G, Friedman E, Gershoni Baruch R (2006). The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Familial Cancer. 5:389-95.

Dagan E, Gil S, Gershoni-Baruch R (2008). Socio-demographic and clinical profile of BRCA1/2 mutation carriers opting for prophylactic oophorectomy. Preventive Medicine. 46:470-2.

Dagan E (2008). Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. Genetic Testing. 12:267-71.

Dagan E andShochat T (2009). Quality of life in asymptomatic BRCA1/2 mutation carriers. Preventive Medicine. 48:193-6.

Bezalel Y,Gershoni-Baruch R,Dagan E, Lidar M,Livneh A (2009 suppl. 53). The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in familial Mediterranean fever. Clinical and Experimental Rheumatology. 27:s103.

Dagan E and Goldblatt H (2009). The twilight zone between health and sickness: A qualitative exploration with asymptomatic BRCA1/2 mutation carriers. Women & Health. 49:263-79.

Antoniou AC, et al., and CIMBA group (2009). Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics. 18:4442-56.

Osorio A, et al., and CIMBA (2009). Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer. 101:2048-54.

Shochat T andDagan E (2010). Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer. Journal of Sleep Research. 19:333-40.

Dagan E, Gershoni-Baruch R, Ihab K, Mori A, Amar N, Brik R (2010). MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA. Rheumatology International. 30:633-6.

Baruch Y, Dagan E, Rozenbaum M, Massimo F, Gershoni-Baruch R, Rosner I (2011).MEFV, TNFRSF1A and CARD15 mutation analysis in Behcet's Disease. Clinical and Experimental Rheumatology. In Press.

Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M, Gershoni-Baruch R, Goldberg H, Kaufman B, Ben-Baruch N, Zidan J, Maray T, Soussan-Gutman L, Friedman E (2011). Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat. In Press